Factoring in API business’ spinoff + a strong Q1
18/05/22 -"We have updated our model to incorporate the impact of the spin-off of the API (active pharmaceutical ingredient) business, which had listed separately as EUROAPI – now part of the NAV as an equity ..."
Pages
67
Language
English
Published on
18/05/22
You may also be interested by these reports :
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...
30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...
29/10/25
The Q3 results exceeded expectations, driven by strong growth in the HIV, respiratory, immunology, oncology, and vaccines portfolio. Consequently, ...
28/10/25
The Q3 operating profitability was slightly behind the street’s expectations, though sales were in line with consensus. The quarterly performance was ...